Consensus Valerio Therapeutics London S.E.

Equities

0NWK

FR0010095596

Market Closed - London S.E. Other stock markets 06:18:08 2020-11-30 EST			5-day change	1st Jan Change
0.7551 ^EUR	-0.52%		+514.40%	+335.72%

05-22	Valerio Therapeutics S.A. Provides Clinical Development Update on Its Phase 1/2 VIO-01 Clinical Trial	CI
04-30	Valerio Therapeutics Société anonyme Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Evolution of the average Target Price on Valerio Therapeutics

Price target over the last 5 years

History of analyst recommendation changes

475064a6842149ca85.kTRzIc5j9uhD5Xpp0mpQ8T-rXoHf46J-9DhhTH4cOdE.2lYUdv4OpNoZrDQxmAA4vG3NCcLqtfYTlUhRNSReYZOgfkVyoCKPqTCuEQ~39a05237a5a477bc15eb5c94d8722a60

Analyst Recommendations on Valerio Therapeutics

Onxeo : Bryan Garnier & Co initiates the coverage of Onxeo with a “Buy” recommendation	20-05-29	PU
Bryan Garnier & Co Initiates Coverage of Onxeo with a “Buy” Recommendation	20-05-27	GL
Onxeo : Bryan Garnier & Co Initiates the Coverage of Onxeo with a “Buy” Recommendation	20-05-27	BU

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.108 EUR

Average target price

1.2 EUR

Spread / Average Target

+1,011.11%

High Price Target

1.2 EUR

Spread / Highest target

+1,011.11%

Low Price Target

1.2 EUR

Spread / Lowest Target

+1,011.11%

Consensus detail

Consensus revision (last 18 months)

Annual profits - Rate of surprise

Company calendar